Rituximab Monotherapy for Grade 2-3 Lymphomatoid Granulomatosis with Central Nervous System Involvement in a Patient Receiving Methotrexate for Rheumatoid Arthritis
Lymphomatoid granulomatosis (LYG) is a rare lymphoproliferative disorder (LPD). The optimal management strategy of methotrexate (MTX) related-LPD with central nervous system (CNS) involvement and histological features of LYG remains unclear. We herein report a case of grade 2-3 LYG in a rheumatoid arthritis patient, in which an intracranial mass accompanied by hemorrhaging and pulmonary and skin lesions developed. The patient received successful rituximab monotherapy. The tumor cells in the skin and brain showed monoclonal and oligoclonal proliferation, respectively. Our case suggests that rituximab monotherapy may be effective against MTX-LPD with CNS involvement, especially in cases with LYG histology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - 62(2023), 13 vom: 01. Juli, Seite 1977-1982 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hosoi, Hiroki [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.07.2023 Date Revised 29.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2169/internalmedicine.0636-22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349311900 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349311900 | ||
| 003 | DE-627 | ||
| 005 | 20231226042321.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.0636-22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349311900 | ||
| 035 | |a (NLM)36418093 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hosoi, Hiroki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rituximab Monotherapy for Grade 2-3 Lymphomatoid Granulomatosis with Central Nervous System Involvement in a Patient Receiving Methotrexate for Rheumatoid Arthritis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.07.2023 | ||
| 500 | |a Date Revised 29.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Lymphomatoid granulomatosis (LYG) is a rare lymphoproliferative disorder (LPD). The optimal management strategy of methotrexate (MTX) related-LPD with central nervous system (CNS) involvement and histological features of LYG remains unclear. We herein report a case of grade 2-3 LYG in a rheumatoid arthritis patient, in which an intracranial mass accompanied by hemorrhaging and pulmonary and skin lesions developed. The patient received successful rituximab monotherapy. The tumor cells in the skin and brain showed monoclonal and oligoclonal proliferation, respectively. Our case suggests that rituximab monotherapy may be effective against MTX-LPD with CNS involvement, especially in cases with LYG histology | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a central nervous system involvement | |
| 650 | 4 | |a lymphomatoid granulomatosis | |
| 650 | 4 | |a lymphoproliferative disorder | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a rituximab monotherapy | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Tanaka, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Sakaki, Ayaka |e verfasserin |4 aut | |
| 700 | 1 | |a Kosako, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Iwamoto, Ryuta |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto, Ai |e verfasserin |4 aut | |
| 700 | 1 | |a Arakawa, Fumiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yamoto, Toshikazu |e verfasserin |4 aut | |
| 700 | 1 | |a Murata, Shogo |e verfasserin |4 aut | |
| 700 | 1 | |a Mushino, Toshiki |e verfasserin |4 aut | |
| 700 | 1 | |a Murata, Shin-Ichi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakao, Naoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ohshima, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Sonoki, Takashi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g 62(2023), 13 vom: 01. Juli, Seite 1977-1982 |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:13 |g day:01 |g month:07 |g pages:1977-1982 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.0636-22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 13 |b 01 |c 07 |h 1977-1982 | ||